Gilead Sciences, Inc. (NASDAQ:GILD)  plans to present over 20 research abstracts—spanning both Gilead and its cell therapy unit Kite—at two major medical conferences: the 2025 ASCO Annual Meeting (May ...

After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all ...

Restaurants will continue to thrive by empowering a future-ready workforce and embracing technology to unleash breakthrough ...

"Ransomware has evolved, not in sophistication but in strategy," said Ferhat Dikbiyik, Black Kite. "Since the fall of LockBit and AlphaV ransomware syndicates, the cybercriminal landscape has been ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Domestic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Join host Yumi Stynes for Seen, a new SBS podcast about cultural creatives who have risen to excellence despite a role-model vacuum. Get the latest with our SBS podcasts on your favourite podcast ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

Lee and Jenni Percy, from Llandrindod Wells, have received a Silver Kite Award from Councillor Jonathon Wilkinson for their work and success in transforming the lakeside area into a principal town ...